Name:
Detraven tabl. MNNDiosmin + hesperidin FTHVenotonic and venoprotective agent
Description:
Film-coated tablets, pink, oval, with a biconvex surface. Composition One tablet contains: active ingredients: a mixture of diosmin-hesperidin (90:10) in terms of the total content of flavonoids – 500 mg; excipients: gelatin, talc, magnesium stearate, sodium starch glycolate, microcrystalline cellulose, opadry 200 F (polyvinyl alcohol; partially hydrolyzed; titanium dioxide E 171; talc; macrogol 3350 (polyethylene glycol); methacrylic acid copolymer type C; iron oxide yellow E 172; iron oxide red E 172; sodium bicarbonate E 500ii; iron oxide black E 172). Pharmacotherapeutic group Means that reduce capillary permeability. Bioflavonoids. ATX code: C05CA53 Pharmacological properties Pharmacodynamics The drug Detraven® has venotonic and angioprotective properties. The drug reduces vein extensibility and venous stasis, reduces capillary permeability and increases their resistance, improves lymphatic drainage, increases lymphatic outflow. The optimal ratio of dose and effect is observed when taking 2 tablets. Therapeutic efficacy has been proven in the treatment of functional and organic chronic venous insufficiency of the lower extremities, as well as in proctology in the treatment of hemorrhoids. Pharmacokinetics Absorption In the gastrointestinal tract, diosmin is rapidly processed by the parietal (intestinal) microflora and absorbed into the blood in the form of aglycone – diosmetin, soluble in lipids. Unprocessed forms of diosmin are not absorbed. Distribution Diosmetin is very quickly redistributed by the blood to the tissues. Animal studies using radioactively labeled diosmin have shown a wide distribution of its metabolites throughout the body. The maximum concentration of diosmetin in the blood is observed 1-3 hours after oral administration of diosmin. Metabolism The drug is extensively metabolized, as evidenced by the presence of various phenolic acids in the urine. Withdrawal Excretion of the drug occurs mainly with feces; urinary excretion averages 14% of the dose taken. The half-life is 11 hours. Indications for use – Treatment (as part of complex therapy) of symptoms of venous-lymphatic insufficiency (heaviness, swelling and pain in the legs, trophic disorders). – Treatment (as part of complex therapy) of symptoms associated with an acute attack of hemorrhoids. Contraindications Hypersensitivity to the active substance or any of the excipients. Method of administration and doses Treatment of symptoms of venous insufficiency: 2 tablets per day (noon and evening) with meals. Acute hemorrhoids: First 4 days: 6 tablets per day (3 tablets in the morning and 3 tablets in the evening). Next 3 days: 4 tablets per day (2 tablets in the morning and 2 tablets in the evening). Apply during meals. Side effects The following side effects or events have been reported, the frequency is indicated depending on the occurrence of the case: very often (? 1/10), often (<1/10 and ? 1/100), infrequently (< 1/100 and ? 1 /1000), rare (<1/1000 and ?1/10000), very rare (<1/10000), frequency unknown (cannot be estimated from the available data). From the nervous system: rarely - dizziness, headache, general malaise. From the digestive system: often - diarrhea, nausea, vomiting, dyspepsia; infrequently - colitis. Skin and subcutaneous tissue disorders: rarely - rash, itching, urticaria; frequency unknown - isolated swelling of the face, lips, eyelids; in exceptional cases - angioedema. Precautions In acute attacks of hemorrhoids, the use of this drug does not replace the special treatment of other diseases of the anorectal region. Treatment should be given in a short course. If the symptoms do not resolve quickly, a proctologic examination should be performed and treatment reviewed. For disorders affecting the venous circulation, treatment has the maximum effect with a balanced lifestyle. Avoid prolonged exposure to the sun, prolonged standing on your feet, weight gain. Hiking improves circulation. Patients should strictly follow the additional medical measures prescribed by the doctor, such as wearing compression medical knitwear (socks, stockings), compresses, cool showers on the lower extremities, etc. Use in children Do not use in children. Use during pregnancy or lactation In the course of numerous studies, a teratogenic effect has not been found and there have been no reports of adverse events in humans. Due to the lack of data on the excretion of the drug into breast milk, breast-feeding during treatment should be avoided. The ability to influence the reaction rate when driving vehicles or other mechanisms The drug does not affect the ability to drive vehicles and perform work that requires a high speed of psychomotor reactions. Interaction with other medicinal products No interaction studies have been conducted. At the same time, taking into account the vast post-marketing experience with similar drugs, drug interactions have not been reported. Overdose: No cases of overdose have been reported. Packing: 10 tablets in a blister pack. 3 or 6 blister packs of 10 tablets with a leaflet in a pack of cardboard (No. 10? 3, No. 10? 6). Storage conditions In a place protected from light and moisture, at a temperature not exceeding 30 ° C. Keep out of the reach of children. Shelf life 2 years. Do not use the medicine after the expiration date. Terms of dispensing from pharmaciesWithout a prescription. Buy Detraven tablets p/o 500mg No. 10x6 Price for Detraven tablets p/o 500mg No. 10x6
Detraven tablets p/o 500mg №10×6
$33.00
INN | DIOSMIN+HESPERIDIN |
---|---|
The code | 121 129 |
Barcode | 4 810 201 018 614 |
Dosage | 500mg |
Active substance | Diosmin, hesperidin |
Manufacturer | Borisovsky ZMP, Belarus |
Indications Applications | Treatment (as part of complex therapy) of symptoms of venous-lymphatic insufficiency (heaviness, swelling and pain in the legs, trophic disorders). – Treatment (as part of complex therapy) of symptoms associated with an acute attack of hemorrhoids. |
Contraindications | Hypersensitivity to the active substance or any of the excipients. |
Side effects | From the nervous system: rarely – dizziness, headache, general malaise. From the digestive system: often – diarrhea, nausea, vomiting, dyspepsia; infrequently – colitis. Skin and subcutaneous tissue disorders: rarely – rash, itching, urticaria; frequency unknown – isolated swelling of the face, lips, eyelids; in exceptional cases – angioedema. |
Use during pregnancy and lactation | Forbidden to use |
Application Gender | Any |
Release Form | tablets |
Main Active Substances | Diosmin + Hesperidin |
Composition Means | One tablet contains: active ingredients: a mixture of diosmin-hesperidin (90:10) in terms of the total content of flavonoids – 500 mg; excipients: gelatin, talc, magnesium stearate, sodium starch glycolate, microcrystalline cellulose, opadry 200 F (polyvinyl alcohol; partially hydrolyzed; titanium dioxide E 171; talc; macrogol 3350 (polyethylene glycol); methacrylic acid copolymer type C; iron oxide yellow E 172; iron oxide red E 172; sodium bicarbonate E 500ii; iron oxide black E 172). |
Be the first to review “Detraven tablets p/o 500mg №10×6” Cancel reply
Related products
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Treatment and prevention of hemorrhoids and varicose veins
Reviews
There are no reviews yet.